title: Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
abstract: Soluble guanylate cyclase is a heterodimeric enzyme with a prosthetic heme group that, on binding of its main ligand, NO, generates the second messenger cGMP. Unlike conventional nitrovasodilators, the novel direct NO- and heme-independent soluble guanylate cyclase activator BAY 58-2667 is devoid of non-cGMP actions, lacks tolerance development, and preferentially activates NO-insensitive heme-free or oxidized soluble guanylate cyclase. BAY 58-2667, therefore, represents a novel therapeutic advance in mediating vasodilation. To date, its cardiorenal actions in congestive heart failure (CHF) are undefined. We, therefore, hypothesized that BAY 58-2667 would have beneficial preload- and afterload-reducing actions in experimental severe CHF together with renal vasodilating properties. We assessed the cardiorenal actions of intravenous administration of 2 doses of BAY 58-2667 (0.1 and 0.3 microg/kg per minute, respectively) in a model of tachypacing-induced severe CHF. In CHF, BAY 58-2667 dose-dependently reduced mean arterial, right atrial, pulmonary artery, and pulmonary capillary wedge pressure (from baseline 19+/-1 to 12+/-2 mm Hg). Cardiac output (2.4+/-0.3 to 3.2+/-0.4 L/min) and renal blood flow increased. Glomerular filtration rate and sodium and water excretion were maintained. Consistent with cardiac unloading, atrial and B-type natriuretic peptide decreased. Plasma renin activity (P=0.31) and aldosterone remained unchanged (P=0.19). In summary, BAY 58-2667 in experimental CHF potently unloaded the heart, increased cardiac output and renal blood flow, and preserved glomerular filtration rate and sodium and water excretion without further neurohumoral activation. These beneficial properties make direct soluble guanylate cyclase stimulation with BAY 58-2667 a promising new therapeutic strategy for cardiovascular diseases, such as heart failure.
authors.affiliation: Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA. boerrigter.guido@mayo.edu
authors.forename: Guido
authors.initials: G
authors.lastname: Boerrigter
authors.forename: Lisa C
authors.initials: LC
authors.lastname: Costello-Boerrigter
authors.forename: Alessandro
authors.initials: A
authors.lastname: Cataliotti
authors.forename: Harald
authors.initials: H
authors.lastname: Lapp
authors.forename: Johannes-Peter
authors.initials: JP
authors.lastname: Stasch
authors.forename: John C
authors.initials: JC
authors.lastname: Burnett
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor / Q000037:antagonists & inhibitors; D001565:Benzoates / Q000008:administration & dosage / Q000494:pharmacology*; D001808:Blood Vessels / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects / Q000503:physiopathology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006162:Guanylate Cyclase / Q000378:metabolism*; D006333:Heart Failure / Q000378:metabolism / Q000503:physiopathology*; D006418:Heme / Q000378:metabolism*; D007668:Kidney / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D020097:Natriuretic Peptide, Brain / Q000037:antagonists & inhibitors; D010084:Oxidation-Reduction; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D000071756:Soluble Guanylyl Cyclase; D014664:Vasodilation
chemical_list: D001565:Benzoates; D018160:Receptors, Cytoplasmic and Nuclear; D020097:Natriuretic Peptide, Brain; C480588:BAY 58-2667; D006418:Heme; D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase; D000071756:Soluble Guanylyl Cyclase